
UNE ORGANISATION CENTRÉE SUR LE PATIENT
TRAITEMENT DU CANCER COLORECTAL ET MISES À JOUR SUR LA RECHERCHE CLINIQUE
Month Ending April 28,, 2021
The following colorectal cancer treatment and research updates extend from March 18th, 2021 to April 28th, 2021, inclusive and are intended for informational purposes only.
Ce contenu n'est pas destiné à se substituer à un avis médical professionnel. Consultez toujours votre médecin traitant ou les conseils d'un professionnel de la santé qualifié pour toute question concernant votre santé ou un problème médical. Ne négligez jamais l'avis d'un professionnel de la santé et ne tardez jamais à le solliciter en raison d'un élément que vous avez lu sur ce site web.

CONTENU
1. Phase II LEAP Clinical Trial to Treat mCRC.
2. TRK Fusion Cancer and How to Test For It
3. Une étude de phase II, ouverte et multicentrique, d'un traitement immunothérapeutique pour la population présentant un cancer colorectal métastatique élevé
4. Étude de phase III au centre de cancérologie Odette comparant l'arfolitixorine et la leucovorine : toutes deux en association avec le 5FU, l'oxaliplatine et le bevacizumab chez des patients atteints d'un cancer colorectal avancé
5. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults
6. Aspirin Tied to Reduced CRC Risk

7. Hepatic Artery Infusion Pump (HAIP) Chemotherapy Program – Sunnybrook Hospital
8. Living Donor Liver Transplantation pour les métastases hépatiques du cancer colorectal non résécable

9. Study Offered at the Odette Cancer Centre to Treat Recurrent Rectal Cancer

10. Trends in the Incidence of Young-Onset CRC with a Focus on Years Approaching Screening Age
11. Calgary Clinic Emerges as a Research Leader in Canada’s Battle Against Colon Cancer
12. Mayo Study Finds Colon Cancer Driven by Hereditary Gene Mutations in 1 in 6 Patients
13. Stool-based CRC Screening Preferred Over Colonoscopy

14. Young Adult CRC Clinic Available at Sunnybrook Hospital
15. Registration is Now Open For CCRAN’s Early Age Onset CRC Virtual Symposium
16. Determining Priority Access to Comprehensive Genomic Profiling for Canadian Cancer Patients
17. Does Crohn’s Disease Affect Your Cancer Risk?
18. CCRAN’s Spring Newsletter Just Out

19. CRC Survivors Ask: What Can I Do Now?

20. NACI Considering Changes to AstraZeneca Age Recommendations
21. Canada Purchases 8M More Pfizer Doses as Moderna Vaccine Shipment Cut Nearly in Half
22. Results of the Safety and Immune-Efficacy of 1 Versus 2 Doses of COVID-19 Vaccine for Cancer Patients
23. So far, 5,800 fully vaccinated people have caught Covid anyway in US
24. CDC Study Finds Pfizer, Moderna Vaccines are 90% Effective After Two Doses in Real-World Conditions
25. AstraZeneca Safe for Canadians as Young as 30, Vaccine Panel Says
26. The Latest on COVID-19
27. COVID-19 Vaccines Are Still Effective Amid Rising Number of Variants
28. Cancer Patient Advocacy Groups Urge the Prime Minister and Premiers to Help Our Cancer Patients Complete the Vaccine Series within the Clinical Trial Recommended Timeline!
29. Foire aux questions pour COVID-19
MÉDICAMENTS / THÉRAPIES SYSTÉMIQUES
- Essai clinique LEAP de phase II pour le CCRm (1er Mars 2020)
Le but de cette étude est de déterminer la sécurité et l'efficacité de la thérapie combinée avec le pembrolizumab (MK-3475) et la levantine (E7080/MK-7902) chez les patients atteints de cancer du sein triple négatif (TNBC), de cancer des ovaires, de cancer gastrique, de cancer colorectal (CCR), de glioblastome (GBM) ou de cancers des voies biliaires (BTC). Les participants seront inscrits dans des cohortes initiales spécifiques aux tumeurs, qui seront élargies si une efficacité adéquate est déterminée. L'essai est disponible au centre de cancérologie Odette et au centre de cancérologie Princess Margaret à Toronto ainsi que dans les centres suivants au Canada : Abbotsford, BC; Winnipeg, MB; CHU de Québec. Pour plus d'informations, consultez le lien ci-dessous.
- TRK Fusion Cancer And How to Test For It (Feb.16/21)
https://www.bayer.ca/en/media/news/?dt=TmpBPQ==&st=1
- A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment for the MSI High CRC Metastatic Population (Oct.01/20)
L'objectif de cette étude est d'examiner l'efficacité du vaccin DPX-Survivac en combinaison avec les médicaments cyclophosphamide et l'immunothérapie Pembrolizumab chez les patients atteints de cancers solides identifiés comme étant des IMS-E. Tous les patients recevront une thérapie combinée de DPX-Survivac, de cyclophosphamide et de pembrolizumab. Les patients participants sauront quel traitement ils reçoivent. L'essai est actuellement mené au centre de cancérologie Odette, et un nouveau site est en cours d'ouverture à l'hôpital Mont Sinaï.
- Étude de phase III au centre de cancérologie Odette Comparing Arfolitixorin vs. Leucovorin in Combination with 5FU, Oxaliplatin and Bevacizumab in Patients with Advanced CRC (Oct.01/20)
The purpose of this study is to look at the effectiveness of the drug Arfolitixorin in combination with 5-fluorouracil (5FU), oxaliplatin, and bevacizumab in patients with colorectal cancer (CRC). Patients with advanced/metastatic CRC who meet certain criteria may be able to participate. There will be two groups of patients participating in this study;
- un groupe recevra de l'arfolitixorine en combinaison avec du 5FU), de l'oxaliplatine et du bevacizumab,
- tandis que l'autre groupe recevra le médicament Leucovorin en combinaison avec le 5FU, l'oxaliplatine et le bevacizumab (norme de soins).
Le médecin et le personnel de l'étude ne sauront pas dans quel groupe se trouve un patient. Les patients seront répartis au hasard pour recevoir l'un ou l'autre traitement.
A propos d'Arfolitixorine:
L'arfolitixorine is Isofol’s proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced CRC. The drug candidate is currently being studied in a global Phase 3 clinical trial. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced CRC, as it does not require complicated metabolic activation to become effective.
Traiter les patients atteints de cancer avec de l'arfolitixorine - Les objectifs :
- When treating CRC, for example, arfolitixorin is administered in combination with 5-FU to increase cell mortality in circulating cancer cells and in cancerous tumours.
- Arfolitixorin is administered in conjunction with rescue therapy after high-dose treatment with the cytotoxic agent, methotrexate, in order to suppress the cytotoxic effect in surrounding healthy tissue. The treatment is used for certain types of cancer, such as osteosarcoma, a type of bone cancer. This involves administering arfolitixorin separately, 24 hours after the chemotherapy.
https://sunnybrook.ca/trials/item/?i=293&page=49335 et https://clinicaltrials.gov/ct2/show/NCT03750786
(https://isofolmedical.com/arfolitixorin/ )
- Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults (Apr.26/21)
The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved by Health Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. These NTRK gene fusions are responsible for both the initiation and maintenance of cancer. They are found in most tumour types at a low frequency (<5%), and at a higher frequency (>80%) in a small number of rare tumours (e.g., secretory carcinoma of the salivary gland and of the breast). Larotrectinib and entrectinib have demonstrated impressive overall response rates and tolerability in Phase I/II trials in patients with TRK fusion cancer with no other effective treatment options. Currently, a major challenge is identifying TRK fusion cancer in a methodologically consistent way that is economically feasible in a public healthcare system.
Ideally, all patients could be tested with a comprehensive next generation sequencing (NGS) panel for all possible actionable cancer alterations at diagnosis. This detects NTRK1, NTRK2, and NTRK3 gene fusions in DNA or RNA. With a plethora of new targets being identified, it is envisioned that in future, the massively parallel analysis of large NGS panels will become routine standard of care for all solid tumours. However, since this is not currently feasible in Canada, strategies for NTRK-positive patient enrichment and NTRK screening must be deployed.
In current circumstances, a pan-TRK immunohistochemistry (IHC) screen, which detects TRKA, TRKB, and TRKC protein, is recommended in patient populations as described who are wildtype for other known oncogenic drivers. Patients whose tumours test positive or are inconclusive by IHC should then receive confirmatory NGS. Researchers recommend a selective TRK inhibitor in all patients with TRK fusion cancer with no other satisfactory treatment options.
This consensus is intended to offer general principles and should be adapted according to the tumour histology and the testing methods/procedures available at each individual Canadian solid tumour biomarker lab, at the discretion of the pathologist and molecular lab director.
https://www.mdpi.com/1718-7729/28/1/53/htm
- Aspirin Tied to Reduced CRC Risk (Apr.26/21)
Regular aspirin use is associated with a reduced risk for developing colorectal cancer (CRC) in older age — but you won’t get the benefit if you start the therapy too late in life, according to a Harvard study published online Jan. 21, 2021, by JAMA Oncology.
Researchers combined the results of two studies involving a total of more than 94,000 people who answered health questionnaires regularly and were followed for three decades. Compared with people who didn’t take aspirin, people ages 70 or older who took either 325 milligrams (mg) or 81 mg of aspirin at least twice per week had a 20% lower risk for developing CRC — but only if they had started the therapy by age 65. Starting aspirin therapy at or after age 70 was not associated with significant protection against CRC. Like any medicine, aspirin isn’t risk-free: regular use increases the risk for gastrointestinal bleeding. If you happen to be taking aspirin regularly for other reasons, this might be an added benefit.
https://www.health.harvard.edu/cancer/harvard-finding-aspirin-tied-to-reduced-colorectal-cancer-risk
LES THÉRAPIES CHIRURGICALES
7. Programme de chimiothérapie par pompe à perfusion dans l'artère hépatique (PPAH) - Centre du cancer Sunnybrook Odette (16 Juil 2020)
Le programme PPAH est une première au Canada pour les personnes dont le cancer du côlon ou du rectum (cancer colorectal) s'est propagé au foie et ne peut être retiré par une intervention chirurgicale. Le programme implique une approche coordonnée et multidisciplinaire des soins, avec une étroite collaboration entre l'oncologie chirurgicale, l'oncologie médicale (chimiothérapie), la radiologie interventionnelle, la médecine nucléaire et les soins infirmiers en oncologie. La pompe à perfusion de l'artère hépatique (PPAH) est un petit dispositif en forme de disque qui est chirurgicalement implanté juste sous la peau du patient et est relié par un cathéter à l'artère hépatique (principale) du foie. Environ 95 % de la chimiothérapie administrée par cette pompe reste dans le foie, épargnant ainsi le reste du corps des effets secondaires. Les patients reçoivent une chimiothérapie dirigée par PPAH en plus de la chimiothérapie intraveineuse (IV) régulière (chimiothérapie systémique), afin de réduire le nombre et la taille des tumeurs. Les docteurs Paul Karanicolas et Yooj Ko sont les responsables du programme et sont heureux de voir les patients éligibles pour la thérapie.
Maintenant au centre de cancérologie Odette, le PPAH est utilisé chez les patients atteints d'un cancer colorectal qui s'est propagé au foie et qui ne peut être enlevé chirurgicalement et ne s'est pas propagé à d'autres parties du corps. Les patients qui ont peu (1-5) et de très petites tumeurs dans les poumons peuvent être pris en considération si la maladie pulmonaire est jugée traitable avant le PPAH. Si vous pensez pouvoir bénéficier de cette thérapie et/ou si vous souhaitez en savoir plus sur l'essai clinique, votre oncologue médical ou votre chirurgien peut vous adresser par télécopie au 416-480-6179. Pour plus d'informations sur l'essai clinique PPAH, veuillez cliquer sur le lien fourni ci-dessous
http://sunnybrook.ca/content/?page=colorectal-colon-bowel-haip-chemotherapy
8. Transplantation de foie de donneur vivant pour les métastases hépatiques du cancer colorectal non résécable (12 Juil 2020)
Environ la moitié des patients atteints de cancer colorectal (CCR) développent des métastases, généralement au niveau du foie et des poumons. L'ablation chirurgicale des métastases hépatiques (MH) est la seule option de traitement, bien que seulement 20 à 40 % des patients soient candidats à un traitement chirurgical. La thérapie chirurgicale apporte un avantage significatif en termes de survie, avec une survie à 5 ans après résection du foie de 40 à 50 % pour les MH, contre 10 à 20 % pour la chimiothérapie seule. La transplantation du foie (TF) permettrait d'éliminer toute maladie évidente dans les cas où les métastases colorectales sont isolées au foie mais considérées comme non résécables.
Source de l'image : https://www.slideshare.net/AhmedAdel65/preoperative
Alors que la MH du CCR est considérée comme une contre-indication à la TF dans la plupart des centres de cancérologie, un seul centre à Oslo, en Norvège, a démontré une survie à 5 ans de 56 %. Un essai clinique parrainé par le University Health Network de Toronto proposera une transplantation de foie de donneur vivant (TFDV) à certains patients présentant des métastases non résécables limitées au foie et ne progressant pas sous chimiothérapie standard. Les patients seront examinés pour déterminer si la greffe de foie est appropriée et doivent également avoir un donneur vivant en bonne santé qui se présente pour l'évaluation. Les patients qui subissent une TFDV seront suivis pendant 5 ans pour leur survie, leur survie sans maladie et leur qualité de vie et comparés à un groupe témoin qui abandonne l'étude avant la transplantation pour des raisons autres que la progression du cancer. Malgré le résultat négatif de l'essai, la recherche sur l'HIPEC et d'autres stratégies de prévention des métastases péritonéales devrait se poursuivre, concluent-ils dans Gastroentérologie Et Hépatologie Lancet."La récurrence péritonéale de 21 % observée dans l'ensemble de la population étudiée indique l'ampleur du problème clinique dans le cancer du colon localement avancé, et les stratégies thérapeutiques doivent être explorées plus avant", ont-ils déclaré. "Les résultats d'autres essais portant sur l'adjuvant HIPEC sont attendus avec impatience"
LES RADIOTHÉRAPIES/RADIOLOGIE INTERVENTIONNELLE
9. Study Offered at the Odette Cancer Centre to Treat Recurrent Rectal Cancer (Mar.12/20)
L'échographie focalisée guidée par résonance magnétique (EFG-RM) est une modalité moins invasive et ambulatoire qui est étudiée pour le traitement thermique du cancer. Dans le EFG-RM, un transducteur spécialement conçu est utilisé pour focaliser un faisceau d'énergie ultrasonore de faible intensité dans un petit volume à un endroit spécifique du corps. La RM est utilisée pour identifier et délimiter la tumeur, focaliser le faisceau d'ultrasons sur la cible et fournir une cartographie thermique en temps réel pour assurer un chauffage précis de la cible désignée avec un effet minimal sur les tissus sains adjacents. Le faisceau ultrasonore focalisé produit une hyperthermie thérapeutique (40-42°C) dans le champ de la cible, provoquant la dénaturation des protéines et des lésions cellulaires. Actuellement, aucune donnée clinique prospective n'a été rapportée sur l'utilisation de l'UF-RMg dans le cadre d'un cancer rectal récurrent. Le cancer récurrent du rectum est un problème clinique délicat. Les protocoles de retraitement actuels ont une efficacité limitée. L'ajout de l'hyperthermie à la radiothérapie et à la chimiothérapie peut améliorer la réponse thérapeutique. Grâce aux récents progrès technologiques, les chercheurs émettent l'hypothèse que la EFG-RM est techniquement réalisable et peut être utilisée en toute sécurité en combinaison avec une réirradiation et une chimiothérapie simultanées pour le traitement du cancer du rectum récurrent sans augmentation des effets secondaires. L'étude est proposée au centre de cancérologie d'Odette. Voici le lien vers le protocole de l'étude :
DÉPISTAGE
10. Trends in the Incidence of Young-Onset CRC with a Focus on Years Approaching Screening Age (Apr.10/21)
With recent evidence for the increasing risk of young-onset colorectal cancer (yCRC), the objective of this population-based longitudinal study was to evaluate the incidence of yCRC in one-year age increments, particularly focusing on the screening age of 50 years. The study was conducted using linked administrative health databases in British Columbia, Canada including a provincial cancer registry, inpatient/outpatient visits, and vital statistics from January 1, 1986 to December 31, 2016. We calculated incidence rates per 100,000 at every age from 20 to 60 years and estimated annual percent change in incidence (APCi) of yCRC using joinpoint regression analysis.
3,614 individuals were identified with yCRC (49.9% women). The incidence of CRC steadily rose from 20 to 60 years, with a marked increase from 49 to 50 years. Furthermore, there was a trend of increased incidence of yCRC among women. Analyses stratified by age yielded APCi’s of 2.49% and 0.12% for women aged 30-39 years and 40-49 years, respectively and 2.97% and 1.86% for men. These findings indicate a steady increase over one-year age increments in the risk of yCRC during the years approaching and beyond screening age. These findings highlight the need to raise awareness as well as continue discussions regarding considerations of lowering the screening age.
11. Calgary Clinic Emerges as a Research Leader in Canada’s Battle Against Colon Cancer (Mar.18/21)
A woman in her ’50s enters a building on the University of Calgary’s Foothills campus, making her way up an elevator and through open doors to the waiting room of the Forzani and MacPhail Colon Cancer Screening Centre. After filling out a short questionnaire on her health and lifestyle, she has joined one of the largest research projects in Canada, designed to improve the early detection and prevention of colorectal cancer (CRC). Researchers at the Arnie Charbonneau Cancer Institute, a joint institute of the Cumming School of Medicine (CSM), Cancer Care Alberta and Alberta Health Services, are gathering data from more than 20,000 participants like her. They are investigating the characteristics that could personalize risk prediction and screening pathways and help develop the next generation of screening tests.
“Our goal is to improve screening for CRC and, ultimately, patient outcomes,” says Dr. Robert Hilsden, MD, PhD’01, MSc’96, the research director of the centre. “First, we want to better understand who is at high risk for CRC and who is not, so we know who needs to be screened and how best to do it. Second, we want to improve the screening experience to maximize participation.” The team is building unique repositories of data that include the collection of biospecimens (blood, urine, normal colon tissue) and detailed information about the participant’s medical history, lifestyle, physical activity and diet.
From this work the researchers intend to develop and advocate for improved policy, practice, and personal change to bend the curve and reduce cancer burden in Canada. Dr. Darren Brenner, PhD, the associate research director of the centre, is leading research to understand why CRC is increasing at a steep rate in young men and women, and to predict the impact of reduced screening during the COVID-19 pandemic. Researchers at the facility also conduct clinical studies focused on improving CRC screening and colonoscopy. The centre’s medical director, Dr. Steven Heitman, MD, MSc, has also led the development of colonoscopy upskilling courses and animal simulation models of polyp removal, driving improvements in colonoscopy quality provincially and nationally.
https://www.ucalgary.ca/news/research-leader-canadas-battle-against-colon-cancer
12. Mayo Study Finds Colon Cancer Driven by Hereditary Gene Mutations in 1 in 6 Patients (Apr.23/21)
In the study, published in Clinical Gastroenterology and Hepatology, researchers within the Mayo Clinic Center for Individualized Medicine found 1 in 6 patients with colorectal cancer (CRC) had an inherited cancer-related gene mutation, which likely predisposed them to the disease. In addition, the researchers discovered that 60% of these cases would not have been detected if relying on a standard guideline-based approach. The patients were tested with a sequencing panel that included more than 80 cancer-causing or predisposing genes. In comparison, standard panels for CRC only include 20 or fewer genes.
“We found that 15.5% of the 361 patients with CRC had an inherited mutation in a gene associated with the development of their cancer,” says Dr. Niloy Jewel Samadder, a Mayo Clinic gastroenterologist and hepatologist, who is the study’s senior author. “We also found that over 1 in 10 of these patients had modifications in their medical or surgical therapy based on the genetic findings.”
In the study, Samadder and his team examined gene variants (mutations) with which the patient was born and that predisposed them to developing cancer. Mutations are abnormal changes in the DNA of a gene. A gene mutation can affect the cell in many ways, including interfering with proteins or causing a gene to be activated. Although many mutations that cause colorectal cancer happen by chance in a single cell — including from environmental factors, diet, smoking and alcohol use — the study confirms many are inherited mutations that set off a cycle of events that can lead to cancer.
“The power of genetics is that we can foresee the cancer that will develop in other family members,” Samadder says. “This can allow us to target cancer screening to those high-risk individuals and hopefully prevent cancer altogether in the next generation of the family.”
13. Stool-based CRC Screening Preferred Over Colonoscopy (Apr.22/21)
“Although several colorectal cancer (CRC) screening methods have been shown to reduce CRC, nearly one-third of eligible adults in the United States have never completed CRC screening and CRC screening continues to be underutilized,” Xuan Zhu, PhD, senior health services analyst at the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and colleagues wrote. “Recommended CRC screening modalities vary with respect to safety, efficacy and cost. Better understanding of the factors that influence patient preference is, therefore, critical for improving population adherence to CRC screening.”
Researchers surveyed 1,062 participants (aged 45-75 years) with an average risk for CRC to investigate preferences among three commonly used CRC screening modalities. The survey informed participants on each screening option, fecal immunochemical test or guaiac-based fecal occult blood test (FIT/gFOBT), multi-target stool DNA test (mt-sDNA) and colonoscopy, and asked participants to choose between two presented options at a time.
When given the choice, 65.4% of respondents chose mt-sDNA over colonoscopy and 61% of respondents chose FIT/gFOBT over colonoscopy; among stool-based screening options, 66.9% of respondents chose mt-sDNA over FIT/gFOBT. According to further study analysis, a larger proportion of younger respondents (aged 45-54 years), Hispanic and non-Hispanic Black respondents and uninsured respondents preferred stool-based testing over colonoscopy. The overall awareness of stool-based testing was lower than colonoscopy awareness (60% vs. 90%) and prior experience was a significant driver for what a respondent chose in the present survey.
“These findings [of patient preference for stool-based tests] underscore the importance of continuing to offer CRC screening options to patients and encourage health care providers to engage their patients in shared decision-making to discuss various available CRC screening options in alignment with patient needs and preferences,” Zhu told Healio.
Source de l'image : https://synappsehealth.com/en/articles/i/the-faecal-occult-blood-test-fobt-what-is-it-and-how-to-prepare-for-it/
AUTRE
14. Young Adult CRC Clinic Available at Sunnybrook (Mar.12/20)
Une étude récente menée par les médecins de l'université de Toronto a observé une augmentation des taux de cancer colorectal chez les patients de moins de 50 ans. Cette étude reflète les résultats obtenus aux États-Unis, en Australie et en Europe. L'augmentation des taux de cancer colorectal chez les jeunes survient après des décennies de baisse des taux chez les personnes de plus de 50 ans, qui s'expliquent très probablement par le recours accru au dépistage du cancer colorectal (par le biais de programmes de dépistage en population) qui permet d'identifier et d'éliminer les polypes précancéreux. Les patients diagnostiqués avant 50 ans ont un ensemble unique de besoins, de défis et d'inquiétudes. Ils sont différents de ceux qui ont été diagnostiqués après 50 ans. Le Dr Shady Ashamalla (oncologue chirurgien spécialisé dans le cancer colorectal) et son équipe du Centre des sciences de la santé Sunnybrook comprennent les besoins de cette population de patients.
Le Dr Ashamalla fait partie d'une équipe multidisciplinaire d'experts de La Clinique Du Cancer Colorectal Des Jeunes Adultes qui travaillera avec les jeunes patients atteints de cancer colorectal, quel que soit le stade de la maladie, afin de créer un plan de traitement individualisé pour soutenir chaque patient dans son parcours contre le cancer. Leurs besoins et leurs préoccupations seront pris en compte dans la mesure où ils s'y rapportent :
- Préoccupations et questions relatives à la fécondité
- Les jeunes enfants à la maison
- Questions relatives aux données et à l'intimité
- Les défis au travail
- Inquiétudes concernant le cancer héréditaire
- Relations avec la famille et les amis
- Stress psychologique dû à l'un ou à l'ensemble des éléments ci-dessus
L'équipe d'experts est composée de :
- Oncologues (médicaux, chirurgicaux, radiologiques)
- Travailleurs sociaux
- Psychologues
- Généticiens
- Infirmière navigatrice
Si un patient souhaite être orienté vers Sunnybrook, il peut demander à son médecin traitant ou à son spécialiste de l'orienter vers Sunnybrook via le formulaire d'orientation électronique, accessible via le lien figurant ci-dessous. Une fois l'orientation reçue La Clinique Du Cancer Colorectal Des Jeunes Adultes sera informée si le patient a moins de 50 ans. Un rendez-vous sera alors fixé, au cours duquel le patient rencontrera différents membres de l'équipe afin de répondre à leurs préoccupations spécifiques.
http://sunnybrook.ca/content/?page=young-adult-colorectal-cancer-clinic
15. Registration is Now Open For CCRAN’s Early Age Onset CRC Virtual Symposium (Apr.27/21)
The incidence of colorectal cancer has been declining in Canadians over 50 years of age, largely due to population-based screening programs. Rates, however, are on the rise in adults younger than 50 years. There is considerable evidence that “the increased incidence of colorectal cancer among younger adults in Canada is not only continuing but possibly accelerating.” In response to the findings and the growing number of young patients seeking support, education, and advocacy for advanced colorectal cancer, CCRAN is hosting its first of three complimentary symposia to be held virtually on June 17, 2021. Over the course of these three symposia, CCRAN will educate on, strategize, and implement a response to the rise in early age onset colorectal cancer (EAOCRC). We encourage all stakeholders, including patients and caregivers, to participate in our symposium on June 17, 2121. Please see graphic appearing below for registration details.

- Determining Priority Access to Comprehensive Genomic Profiling for Canadian Cancer Patients (Apr.28/21)
It has become increasingly apparent that in order to select the best cancer treatment, a comprehensive picture of the tumour at the DNA level is needed. Thus, the idea of using a tumour’s unique genomic fingerprint to match patients to their most effective treatment is the cornerstone of precision (or personalized) medicine. In fact, over 20 cancer therapies linked to over 15 genomic biomarkers have been approved in Canada, with many more quickly emerging.
Currently, the most frequently available molecular tools for cancer patients are single-gene companion diagnostic tests or limited gene panel tests that detect only “hot-spots” for certain genomic alterations. However, with the growing number of therapeutically relevant genomic biomarkers across all tumour types, these tests cannot truly capture a comprehensive view of a tumour’s genomic profile. For instance, when testing of several genomic biomarkers are needed, the sequential nature of single-gene tests presents limitations, which lead to patients being unable to receive testing for all relevant genomic biomarkers and patients missing opportunities for critical, biomarker-matched therapy. “Hotspot” gene panels can avoid some of the limiting factors of single-gene tests; however, they present with other challenges that result in missed opportunities for cancer patients to be treated with their optimal genomic biomarker-matched therapy.
Comprehensive genomic profiling (CGP), can fill the gaps left by single-gene and hot-spot panel testing by taking advantage of next-generation sequencing (NGS) technology which can:
- Accurately sequence a large number of genes simultaneously in a cost-, time-, and tissue-efficient manner.
- Simultaneously identify several different types of genomic alterations, as well as genome-wide changes.
- Easily adapt to include new genomic biomarkers as they become relevant, with minimal increased cost; and
- Potentially eliminate the need for re-sequencing tissue once new biomarker information is available, as initial CGP data can be re-evaluated.
This report provides a list of recommendations to aid decision-makers in this process.
- All patients with advanced or metastatic solid tumours should have access to CGP where deemed necessary or valuable by their clinician.
- Given budgetary constraints, tumour types that currently have five or more genomic biomarkers linked to approved therapies should be prioritized for CGP funding to replace current limited testing modalities.
- Decision-makers must remain cognizant of the many other tumour types which will soon reach the five-biomarker threshold and be able to respond quickly or proactively to provide CGP funding for these patients.
- Any patient with an advanced or metastatic solid tumour who is refractory to standard therapy or is lacking treatment options that could extend survival should be prioritized for CGP.
- Stakeholders should collaborate to establish a new framework for assessing the value of CGP and new genomic biomarker-matched therapies that consider non-traditional methodologies.
- Does Crohn’s Disease Affect Your Cancer Risk? (Apr.08/21)
What is Crohn’s disease?
Crohn’s disease is a chronic inflammatory bowel disorder that can affect the entire gastrointestinal tract. It usually targets the end of the small intestine or the colon. Research suggests that the cause may be related to the balance of good and bad bacteria in the gut microbiome. The most common symptoms of Crohn’s disease are diarrhea, blood in your stool, abdominal pain and weight loss.
How does Crohn’s disease affect colorectal cancer risk?
Crohn’s disease is an autoimmune process that causes the body to attack its own tissue. The resulting long-term injury to the GI tract causes the inflamed areas to be in a constant state of repair and inflammation. “Your body is replenishing the cells that are damaged repeatedly. Sooner or later, with this constant turnover, an error in the replaced cells can result in cancer,” says Anusha Thomas, M.D., a gastroenterologist at MD Anderson West Houston. “The longer this process goes on, the higher the chance that these faulty cells become cancer.” Although Crohn’s can affect all areas of the GI tract and other areas of the body, cancers outside the small intestine, colon, rectum, or anus are rare.
How can you reduce your risk of cancer if you have Crohn’s disease?
While there is no cure for Crohn’s disease, it can be managed with medication. “The goal is to control the inflammation,” says Thomas. “If we can control the inflammation, we worry less about cancer. Once the disease is diagnosed, we follow patients with routine surveillance.” Surveillance includes regular visits with your doctor to manage your medication and regular screening exams. If you have had Crohn’s disease for eight years or more, you should get a colonoscopy every 1 to 2 years. The longer there is inflammation, the higher the risk of cancer.
“With inflammatory bowel disease, the sooner you get a diagnosis, the faster you can get your symptoms under control, reduce inflammation and reduce the risk of cancer,” says Thomas. Crohn’s disease and colon cancer symptoms may overlap. Early detection is also key. The earlier cancer is detected, the better the chances of it being treated successfully.
https://www.mdanderson.org/cancerwise/does-crohns-disease-affect-your-cancer-risk.h00-159460056.html
18. CCRAN’s Spring Newsletter Just Out!
Welcome to the Spring edition of CCRAN’s Newsletter containing rich and exciting updates in CCRAN’s programs and activities. Click on the page below to access the newsletter and important links.

NUTRITION/MODE DE VIE SAIN
19. Colorectal Cancer Survivors Ask: What Can I Do Now? (Apr.22/21)
Carol A. Burke, MD, the vice chair of the Department of Gastroenterology, Hepatology and Nutrition at Cleveland Clinic in Cleveland, and the head of the polyposis section in the Sanford R. Weiss, MD Center for Hereditary Colorectal Neoplasia, noted that many common diseases in Western populations, including colorectal cancer (CRC), have links to lifestyle. She added that four healthy behaviors can help prevent CRC and reduce the risk for poor outcomes after diagnosis: maintaining a normal body mass index, avoiding smoking, engaging in recommended levels of aerobic and muscle strengthening exercise, and eating a plant-based diet low in animal fats and processed foods.
Benefits of Exercise
In a meta-analysis of 49,000 survivors of CRC and breast cancer, physical activity had a dose-related effect on survival after CRC diagnosis. Reduction in mortality risk ranged from 15% for 5 metabolic equivalent of task [MET] hours per week of exercise to 38% for 15 MET hours per week. Another type of activity to recommend is resistance training, especially for patients who have lost bone density or muscle function during treatment. Resistance training can improve balance and decrease the risk for falls.
The evidence supporting exercise has been taken up in guidelines from the National Comprehensive Cancer Network (NCCN): 2.5 to 5 hours of moderate-intensity exercise per week (less if exercise is vigorous), or 2 to 3 sessions per week of resistance training. “But recommendations of even light-intensity activity can improve functioning in patients who can’t or won’t do moderate levels of exercise. The big thing is to avoid a sedentary lifestyle,” Dr. Urba said.
Nutrition, Weight Management
The National Surgical and Adjuvant Bowel Project evaluated the association between BMI and outcomes in two randomized trials of adjuvant chemotherapy involving 4,288 CRC patients. Compared with normal-weight people (BMI, 18.5-24.9 kg/m2), very obese patients (BMI =35 kg/m2) had a 38% greater risk for CRC recurrence or a second primary cancer, a 36% increased risk for CRC-related mortality, and a 28% increased risk for death from any cause.
Not only obesity, but diets contributing to it have been linked to outcomes after a diagnosis of CRC. In an adjuvant chemotherapy study involving 1,000 patients with stage II/III CRC, the Cancer and Leukemia Group B trials group queried patients during and six months following adjuvant chemotherapy. Patients in the highest quintile of a Western diet (red meat, fat, refined foods, desserts) versus lowest had double or triple the risk for CRC recurrence and CRC-related death. Patients whose diets reflected a high glycemic index also had worse disease-free survival, recurrence-free survival, and overall survival.
“The NCCN dietary recommendations include high intake of vegetables, fruits, grains, fish and poultry, and a limit on the bad things, including red meat, processed foods and sugars,” Dr. Urba said. These studies are just a small part of a solid foundation of evidence that supports a healthy lifestyle as a means of preventing recurrence of CRC.
Image Source 1: https://www.istockphoto.com/illustrations/home-workout
Image Source 2: https://www.netclipart.com/isee/ioJowi_healthy-food-clipart-eat-well-chart-of-balanced/
MISES À JOUR COVID-19
- NACI Considering Changes to AstraZeneca Age Recommendations (Apr.16/21)
The National Advisory Committee on Immunization (NACI) is considering whether to change its recommendation that the Oxford-AstraZeneca COVID-19 vaccine not be offered to anyone under the age of 55. Health Canada announced earlier this week the vaccine will remain authorized for all adults in Canada after the country reported its first case of blood clots linked to the shot. The agency says the new and extremely rare blood clotting syndrome may be linked to the vaccine, but they concluded the benefits of the shot still far outweigh any risks.
Dr. Susy Hota with the University Health Network says offering the shot to more people makes sense. “As long as people are aware of what the possibility is and they consent to it, I think it’s an important strategy you need to consider,” Hota said. Dr. Daniel Gregson with the University of Calgary says people do riskier things than get the shot on a daily basis without a second thought. “Surely based on risks, most people are much better off with a vaccine than not a vaccine,” he said.
In late March, NACI recommended a pause on AstraZeneca COVID-19 vaccinations for people under 55 due to safety reasons. Health officials continue to urge Canadians to take whichever vaccine is offered to them. More than 700,000 doses of the vaccine have been administered in Canada and about two million doses have been shipped.
The rollout of the Oxford-AstraZeneca vaccine in Canada has been shrouded with confusion, due to safety concerns and changing guidance over who can receive the shot. Health Canada asked AstraZeneca for a full risk assessment of its vaccine after reports of similar clots in Europe, but the agency says the side effect is extremely rare and the vaccine’s benefits still outweigh its risks.
https://www.680news.com/2021/04/16/naci-considering-changes-to-astrazeneca-age-recommendations/amp/
21. Canada Purchases 8M More Pfizer Doses as Moderna Vaccine Shipment Cut Nearly in Half (Apr.16/21)
Canada has purchased an additional eight million doses of the Pfizer-BioNTech COVID-19 vaccine that will be delivered in May, June and July, Prime Minister Justin Trudeau said Friday. The country will receive four million doses in May, two million in June, and another two million in July. The first shipment of Johnson and Johnson one-shot COVID-19 vaccine will be coming on April 27. The 300,000 doses will be distributed the first week of May. The news came shortly after it was announced that a shipment of Moderna vaccines expected next week has been cut nearly in half from 1.2 million to 650,000 doses. “The supplier has also indicated that 1 to 2 million doses of the 12.3 million doses scheduled for delivery in the second quarter may be delayed until the third quarter,” Minister of Procurement Anita Anand added in a statement Friday. Moderna blames slower than anticipated production capacity for the shortfall.
Source de l'image : https://www.cidrap.umn.edu/news-perspective/2020/12/fda-documents-show-pfizer-covid-vaccine-protects-after-1-dose
22. Results of the Safety and Immune-Efficacy of 1 Versus 2 Doses of COVID-19 Vaccine for Cancer Patients (Mar.17/21)
This study presents data on the safety and immune efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine in 54 healthy controls and 151 mostly elderly patients with solid and haematological malignancies, respectively, and compares results for patients who were boosted with BNT162b2 at 3 weeks versus those who were not.
Findings show that the vaccine was largely well tolerated. However, in contrast to its very high performance in healthy controls (>90% efficacious), immune efficacy of a single inoculum in solid cancer patients was strikingly low (below 40%) and very low in haematological cancer patients (below 15%). Of note, efficacy in solid cancer patients was greatly and rapidly increased by boosting at 21-days (95% within 2 weeks of boost). Too few haematological cancer patients were boosted for clear conclusions to be drawn.
Researchers concluded that delayed boosting potentially leaves most solid and haematological cancer patients wholly or partially unprotected, with implications for their own health. Prompt boosting of solid cancer patients quickly overcomes the poor efficacy of the primary inoculum in solid cancer patients.
https://www.medrxiv.org/content/10.1101/2021.03.17.21253131v1
23. So far, 5,800 fully vaccinated people have caught Covid anyway in US (Apr.15/21)
About 5,800 people who have been vaccinated against coronavirus have become infected anyway, the US Centers for Disease Control and Prevention tells CNN. According to the CDC, some became seriously ill, and 74 people died. Additionally, 396 (7%) of those who got infected after they were vaccinated required hospitalization.
“To date, no unexpected patterns have been identified in case demographics or vaccine characteristics,” the CDC told CNN via email. Although rare, breakthrough cases are expected. The vaccines are not 100% effective in preventing infections and as tens of millions of people are vaccinated, more and more such cases will be reported.
Pfizer/BioNTech’s vaccine was 95% effective in preventing symptomatic disease in clinical trials, and earlier this month the companies said real-life data in the US shows the vaccine is more than 91% effective against disease with any symptoms for six months. Moderna’s vaccine was 94% effective in preventing symptomatic illness in trials, and 90% effective in real life use. Johnson & Johnson’s vaccine was 66% overall globally in trials, and 72% effective at preventing disease in the US.
Vaccine breakthrough infections make up a small percentage of people who are fully vaccinated. The likelihood of these “very rare” infections depends on how much virus is circulating within a community, Dr. Kawsar Talaat, an infectious disease physician and assistant professor at Johns Hopkins Bloomberg School of Public Health, told CNN. CDC recommends that all eligible people get a COVID-19 vaccine as soon as one is available to them.
https://www.cnn.com/2021/04/14/health/breakthrough-infections-covid-vaccines-cdc/index.html
Source de l'image : https://medical.mit.edu/covid-19-updates/2021/01/got-vaccine-can-i-toss-my-mask
24. CDC Study Finds Pfizer, Moderna Vaccines are 90% Effective After Two Doses in Real-World Conditions (Mar.29/21)
At full vaccination, the Pfizer and Moderna vaccines were 90% effective at preventing infections, including asymptomatic infections. At least 14 days after first dose but before second dose, they were 80% protective, according to the agency’s Morbidity and Mortality Weekly Report published Monday.
The study assessed how the vaccines protected nearly 4,000 health care workers and first responders. Most of the volunteers of the study (>62%) had received both doses of either a Pfizer or Moderna Covid-19 vaccine. More than 12% had received just a single dose. Among the 2,961 people vaccinated with one or more doses and the 989 unvaccinated participants, a total of 205 had a positive PCR test for Covid-19. 161 infections were identified when participants were unvaccinated, whereas 8 were identified among those partially immunized and 3 were identified among those fully immunized (more than 14 days after their second dose). More than 87% of Covid-19 cases had symptoms. Nearly 23% of the cases sought help from a doctor. There were two hospitalizations, but no deaths.
“This study is tremendously encouraging,” CDC Director Dr. Rochelle Walensky said Monday at the White House Covid-19 briefing. “These findings also underscore the importance of getting both of the recommended doses of the vaccine in order to get the greatest level of protection against Covid-19, especially as our concerns about variants escalate.”
https://www.cnn.com/2021/03/29/health/pfizer-and-moderna-covid-19-vaccines-work-wellness/index.html
- AstraZeneca Safe for Canadians as Young as 30, Vaccine Panel Says (Apr.23/21)
A national advisory panel has recommended Canadians 30 and older can get the Oxford-AstraZeneca vaccine if they don’t want to wait for an alternative, but some provinces say they don’t have enough supply to expand eligibility for the shot. While the committee originally recommended a pause on using AstraZeneca shots for people younger than 55, Health Canada released a safety assessment last week that showed the benefits of the shot outweigh the risks, which the committee said it also evaluated. The committee said the blood clots are rare, and people have an individual choice if they would rather wait to take the Pfizer-BioNTech or Moderna vaccines. The Pfizer-BioNTech and Moderna vaccines use messenger RNA, or mRNA, to trigger an immune response, unlike AstraZeneca, which is a viral-vector vaccine that delivers a safe virus to teach the body to protect against COVID-19.
Although provinces initially suspended giving AstraZeneca shots to younger people based on the committee’s previous advice, Ontario, Manitoba, Saskatchewan, Alberta and British Columbia have since started administering it to people over 40, given the current spread of the virus. Ontario reported its first case on Friday of a rare blood clot in a man in his 60s who received the vaccine, bringing the number of reported cases in Canada to four out of more than 1.1 million doses given, according to the province’s top doctor. Manitoba will also take time to review NACI’s advice, which it said was not a “blanket recommendation” of using this vaccine for all people aged 30 and older, a spokeswoman said in a statement. “Eligibility for AstraZenca will remain at 40 and over until further notice,” the statement said.
Procurement Minister Anita Anand said last week that Canada still expects to receive 4.1 million doses of AstraZeneca from all sources by the end of June. She also said the country can expect to receive around one million doses of Pfizer-BioNTech early next week and 650,000 doses of Moderna by mid-week.
Source de l'image : https://www.dw.com/en/astrazeneca-germany-other-european-countries-to-resume-use-of-vaccine/a-56922088
26. The Latest on COVID-19 (Apr.15/21)
Pfizer CEO says we may need annual vaccinations for COVID-19
The chief executive officer of Pfizer said Thursday that people may need to get a third COVID-19 vaccination within 12 months of being full vaccinated. Albert Bourla added that annual inoculations may be needed to prevent future spread of the disease. Researchers still haven’t determined how long protection against the disease lasts after someone is vaccinated.
Blood clots rare in Moderna, Pfizer vaccines
A new study reports that the number of blood clot cases is about the same for the Moderna, Pfizer-BioNTech, and AstraZeneca vaccines. The researchers said about 4 in 1 million people who get the Moderna or Pfizer-BioNTech vaccine will develop blood clots. The rate is about 5 in 1 million for the AstraZeneca shot. They note that about 39 in 1 million people who develop COVID-19 get blood clots.
India reports 1-day record in COVID-19 cases
India reported a record 200,000 new cases of COVID-19 today, becoming the second country after the United States to reach this single-day toll, reported The Washington Post. These new cases have pushed India’s total cases to more than 14 million and turned the nation into the pandemic’s global epicenter with little indication the outbreak will slow. To contain the COVID-19 surge, Maharashtra Chief Minister Uddhav Thackeray announced curfew-like restrictions on the movement of people in the state from April 14 to May 1, reported The Indian Express.
- COVID-19 Vaccines Are Still Effective Amid Rising Number of Variants (Apr.23/21)
Recent research from Pfizer looked at 44,000 people around the world — including people in South Africa who were predominantly exposed to the B.1.351 variant — and found that the vaccine remained 100% effective against severe disease and death. Real-world data also shows that the Pfizer vaccine held up against the B.1.1.7 variant, which was first detected in United Kingdom. Even in an area where B.1.1.7 was the dominant strain, the shot was 97% effective against symptomatic COVID-19, hospitalizations, and death. Evidence shows that the same is true with the Moderna, AstraZeneca, and Johnson & Johnson vaccines.
Johnson & Johnson vaccine clinical trials were conducted in South Africa and Brazil — both of which were being pummelled by the B.1.351 variant and P.1 variant, respectively, when the trials were conducted. Though the Johnson & Johnson vaccine was less effective overall against mild and moderate disease in South Africa and Brazil, the one-dose shot still provided strong protection against hospitalization and death.
How the immune system fights variants
The immune system is complex, and antibodies alone won’t determine how protected you are against a pathogen, explains Dr. Joseph Craft, a professor of immunobiology and medicine at Yale School of Medicine. The cell-mediated immune response, which includes B-cells that produce antibodies along with T-cells, also mount a robust response against pathogens, often lasting for years. Our antibodies help prevent an infection from occurring by neutralizing a virus, but the T-cells can recognize parts of the virus on infected cells and clear out the infection before it becomes serious. Research shows that T-cells can identify 52 parts of the coronavirus, so even if there are mutations, the T-cell will still recognize and attack the variants.
How long will T-cell protection last?
According to Craft, once our bodies have been exposed to a virus, we’re typically protected against that virus for a long time. A recent study found people had “strong T-cell responses to variants (including B.1.1.7, B.1.351, P.1, and CAL.20C) equal to the T-cell responses you get from the ancestral strain,” explained Dr. Monica Gandhi, an infectious disease specialist with the University of California, San Francisco. Another study found that T-cell immunity might be our greatest weapon at avoiding severe disease since they’re skilled at rapidly clearing viruses. Scientists will need to continue studying T-cell immunity over time to understand just how protective and durable our cell-mediated response is.
Source de l'image : https://www.wwltv.com/article/news/health/supporting-your-immune-system-against-covid-19/289-dc6de4cb-fda6-42fc-b7fd-133e2422f3e0
- Cancer Patient Advocacy Groups Urge the Prime Minister and Premiers to Help Our Cancer Patients Complete the Vaccine Series within the Clinical Trial Recommended Timeline! (Apr.28/21)
Cancer Patient Advocacy Groups, including CCRAN, took out a full-page ad in the Globe & Mail, urging the Prime Minister and provincial Premiers to ensure that cancer patients complete their covid vaccine series within the recommended clinical trial data timelines. Evidence to support the recommended timeline appear below.


29. Foire aux questions pour COVID-19
Qu'est-ce que le COVID-19 (ou nouvelle maladie à coronavirus-19)?
R : Les coronavirus sont une grande famille de virus qui peuvent provoquer des maladies chez les humains et les animaux. Les coronavirus peuvent provoquer des maladies dont la gravité va du simple rhume à des maladies plus graves telles que le syndrome respiratoire aigu sévère (SRAS) et, plus récemment, le COVID-19. Le COVID-19 ou nouveau coronavirus est né d'une épidémie à Wuhan, en Chine, en décembre 2019. Les symptômes les plus courants associés au COVID-19 peuvent comprendre de la fièvre, de la fatigue et une toux sèche. Mais d'autres symptômes ont été associés à la maladie, notamment des douleurs, une congestion nasale, un écoulement nasal, un mal de gorge, de la diarrhée, des éruptions cutanées et des vomissements. Il est également possible d'être infecté par le COVID-19 et de ne présenter aucun symptôme ou de se sentir malade. La propagation de COVID-19 se fait principalement par la transmission de gouttelettes provenant du nez ou de la bouche lorsqu'une personne tousse, expire ou éternue. Ces gouttelettes se posent sur les surfaces autour d'une personne proche. COVID-19 peut être transmis à cette personne proche qui peut finir par toucher la surface contaminée par COVID-19 et ensuite se toucher le nez, la bouche ou les yeux. Une personne peut également contracter COVID-19 en inhalant ces gouttelettes d'une personne atteinte de COVID-19. Bien que les recherches soient toujours en cours, il est important de noter que les populations plus âgées (plus de 65 ans), celles dont le système immunitaire est affaibli et celles qui souffrent d'affections préexistantes, notamment de maladies cardiaques, d'hypertension, de maladies pulmonaires, de diabète ou de cancer, peuvent être plus exposées à une maladie grave due à COVID-19.
https://www.who.int/news-room/q-a-detail/q-acoronaviruses)
Que puis-je faire pour éviter de contracter le coronavirus ?
R : Il y a plusieurs façons de réduire le risque de contracter le COVID-19. Voici quelques mesures suggérées par l'Organisation mondiale de la santé
- Gardez au moins 2 mètres (ou 6 pieds) entre vous et les autres personnes. Cela réduira le risque d'inhaler les gouttelettes des personnes infectées par COVID-19.
- Nettoyez-vous régulièrement les mains pendant au moins 20 secondes avec de l'eau chaude et du savon, ou avec un produit de nettoyage à base d'alcool. Cela permettra de tuer tous les virus présents sur vos mains.
- Évitez de vous toucher les yeux, le nez et la bouche. Si le virus se trouve sur vos mains, il peut pénétrer dans le corps par ces zones.
- Suivez une bonne hygiène respiratoire en vous couvrant la bouche et le nez avec un mouchoir en papier ou le coude lorsque vous toussez et éternuez. Cela empêche les gouttelettes de se déposer sur les surfaces ou d'être libérées dans l'air autour de vous.
- Restez chez vous autant que possible, surtout si vous ne vous sentez pas bien. Si vous pensez être atteint du coronavirus, veuillez consulter la section "Que dois-je faire si je pense être atteint du coronavirus ?
- Veuillez porter un masque ou un couvrevisage en public lorsque la distance physique n'est pas possible.
https://www.who.int/news-room/q-adetail/q-a-coronaviruses
Existe-t-il des traitements contre le coronavirus?
R : Les personnes atteintes d'un cancer sont plus exposées à une maladie grave en raison de la COVID-19, car le cancer est considéré comme un problème de santé préexistant. Certains traitements du cancer, notamment la chimiothérapie, la radiothérapie et la chirurgie, peuvent affaiblir le système immunitaire, ce qui rend l'organisme plus difficile à combattre les infections et les virus, comme le coronavirus. Il est important de suivre avec diligence les recommandations de l'Organisation mondiale de la santé ci-dessus pour réduire le risque de contracter le COVID-19. Si vous avez des inquiétudes quant à votre risque, il est préférable de contacter votre médecin ou votre équipe de soins.
Il n'existe actuellement aucun traitement disponible pour COVID-19, mais des essais sont en cours pour déterminer la meilleure façon de traiter et de gérer les personnes atteintes du virus. Les vaccins candidats sont soumis à des tests rigoureux dans un certain nombre de pays du monde, dont le Canada. Le gouvernement américain finance trois grands essais de phase 3 sur des vaccins potentiels COVID-19 et ces trois essais sont menés par trois sociétés pharmaceutiques différentes qui étudient différents candidats vaccins. L'espoir est de disposer d'un vaccin d'ici la fin de l'année !
Source: https://www.who.int/news-room/q-a-detail/q-acoronaviruses
Y a-t-il des précautions particulières que les personnes atteintes d'un cancer peuvent prendre ?
R : Les personnes atteintes de cancer (et d'autres maladies chroniques telles que les maladies cardiaques, le diabète, l'hypertension et les maladies pulmonaires) sont plus exposées à une maladie grave en raison de la COVID-19, le cancer étant considéré comme un problème de santé préexistant. Certains traitements contre le cancer, notamment la chimiothérapie, les radiations et la chirurgie, peuvent affaiblir le système immunitaire, ce qui rend l'organisme plus difficile à combattre les infections et les virus, comme le Coronavirus. Il est important de suivre avec diligence les recommandations de l'Organisation mondiale de la santé ci-dessus pour réduire le risque de contracter le COVID-19. Si vous avez des inquiétudes quant à votre risque, il est préférable de contacter votre médecin ou votre équipe de soins.
Y a-t-il des changements en ce qui concerne mes visites médicales liées au cancer ? Chaque patient et chaque plan de traitement étant uniques, il est toujours préférable de contacter votre prestataire de soins de santé pour obtenir des informations actualisées sur votre plan de traitement. Dans certains cas, il est possible de retarder le traitement du cancer jusqu'à ce que le risque de pandémie ait diminué. Dans d'autres cas, il peut être sûr de se rendre dans une clinique distincte de celle où sont traités les patients COVID-19. Les options de traitement oral pourraient être prescrites par votre prestataire de soins de manière virtuelle, sans qu'il soit nécessaire de se rendre à la clinique. Enfin, certains rendez-vous ou discussions de suivi pourraient être organisés virtuellement (via skype ou zoom par exemple) ou par téléphone pour minimiser votre risque. Comme nous le savons, les conditions et les protocoles changent quotidiennement en raison de la nature de l'épidémie de COVID-19 et varient en fonction du lieu, par conséquent, la meilleure première étape consiste à demander conseil à votre prestataire de soins.
https://www.cancer.gov/contact/emergencypreparedness/coronavirus
Si vous souhaitez contacter votre agence locale de santé publique, veuillez voir ci-dessous.
Alberta
Informations COVID-19 pour Alberta
Les médias sociaux : Instagram @albertahealthservices, Facebook @albertahealthservices, Twitter @GoAHealth
Numéro de téléphone : 811
Colombie-Britannique
Informations COVID-19 pour Colombie-Britannique
Les médias sociaux : Facebook @ImmunizeBC, Twitter @CDCofBC
Numéro de téléphone : 811
Manitoba
Informations COVID-19 pour Manitoba
Les médias sociaux : Facebook @manitobagovernment, Twitter @mbgov
Numéro de téléphone : 1-888-315-9257
Nouveau Brunswick
Informations COVID-19 pour Nouveau-Brunswick
Les médias sociaux : Facebook @GovNB, Twitter @Gov_NB, Instagram @gnbca
Numéro de téléphone : 811
Terre-Neuve et Labrador
Informations COVID-19 pour Terre-Neuve-et-Labrador
Les médias sociaux : Facebook @GovNL, Twitter @GovNL, Instagram @govnlsocial
Numéro de téléphone : 811 ou 1-888-709-2929
Territoires du Nord-Ouest
Informations COVID-19 pour Territoires du Nord-Ouest
Les médias sociaux : Facebook @NTHSSA
Numéro de téléphone : 811
Nouvelle-Écosse
Informations COVID-19 pour Nouvelle-Écosse
Les médias sociaux : Facebook @NovaScotiaHealthAuthority , Twitter @healthns, Instagram @novascotiahealthauthority
Numéro de téléphone : 811
Nunavut
Informations COVID-19 pour Nunavut
Les médias sociaux : Facebook @GovofNunavut , Twitter @GovofNunavut, Instagram @gouvernement du Nunavut
Numéro de téléphone : 1-888-975-8601
Ontario
Informations COVID-19 pour Ontario
Les médias sociaux : Facebook @ONThealth, Twitter @ONThealth , Instagram @ongov
Numéro de téléphone : 1-866-797-0000
Île-du-Prince-Édouard
Informations COVID-19 pour Île-du-Prince-Édouard
Les médias sociaux : Facebook @GovPe, Twitter @InfoPEI,
Québec
Informations COVID-19 pour Québec
Les médias sociaux : Facebook @GouvQc, Twitter @sante_qc
Numéro de téléphone : 1-877-644-4545
Saskatchewan
Informations COVID-19 pour Saskatchewan
Les médias sociaux : Facebook @SKGov, Twitter @SKGov
Numéro de téléphone : 811
Yukon
Informations COVID-19 pour Yukon
Les médias sociaux : Facebook @yukonhss, Twitter @hssyukon
Numéro de téléphone : 811